MedDataX Logo

Revlite Laser System Compared to the Candela Alex TriVantage System Refractory Mixed Type Melasma

NCT ID: NCT01745224

Last Updated: 2020-12-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

4 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-07-31

Study Completion Date

2013-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This proof of concept study will be conducted to assess the aesthetic improvement in refractory mixed type melasma in subjects treated with two FDA 510K approved devices: Q Switched Nd: YAG Laser vs. Alex TriVantage

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Melasma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This was a comparative study where the device was used outside of the recommended treatment usage. It was used to assess the Revlite device for feasibility and not health outcomes.
Primary Study Purpose

DEVICE_FEASIBILITY

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Revlite Q switched Nd:YAG laser

Revlite Q switched Nd:YAG laser 1064 nm

Group Type EXPERIMENTAL

Revlite Q switched Nd:YAG

Intervention Type DEVICE

Revlite Q switched Nd:YAG 1064nm

Trivantage Q switched Nd: YAG

Intervention Type DEVICE

Trivantage Q switched Nd: YAG 1064nm

TriVantage Q switched Nd:YAG laser

TriVantage Q switched Nd:YAG laser 1064nm

Group Type EXPERIMENTAL

Revlite Q switched Nd:YAG

Intervention Type DEVICE

Revlite Q switched Nd:YAG 1064nm

Trivantage Q switched Nd: YAG

Intervention Type DEVICE

Trivantage Q switched Nd: YAG 1064nm

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Revlite Q switched Nd:YAG

Revlite Q switched Nd:YAG 1064nm

Intervention Type DEVICE

Trivantage Q switched Nd: YAG

Trivantage Q switched Nd: YAG 1064nm

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects with Fitzpatrick Skin Type III-VI
2. Subjects with mixed (epidermal and dermal) type melasma diagnosed by Wood's Lamp.
3. Subjects who are over the age of 18 years of age
4. The subject is willing and able to comply with study instructions and return to the clinic for required visits.
5. The subject's melasma has persisted for greater than 6 months and has failed to respond to conventional treatment with hydroquinone cream or other topical lightening agents.

Exclusion Criteria

1. The subject is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period.
2. The subject has a history of cutaneous photosensitization, porphyria, and hypersensitivity to porphyrins or photodermatosis.
3. The subject has any skin pathology or condition that could interfere with the evaluation or requires the use of interfering topical or systemic therapy.
4. The subject has an uncorrected coagulation defect or is currently using anti-coagulation medication (including but not limited to heavy aspirin therapy).
5. The subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study.
6. The subject is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 30 days prior to entering this study.
7. The subject has used photosensitizing drugs (e.g., Declomycin, sulfa antibiotics, phenothiazines, etc.) within a timeframe where photosensitization from these drugs may still be present.
8. The subject has the need to be exposed to artificial tanning devices or excessive sunlight during the trial.
9. The subject has had prior treatment with parenteral gold therapy (gold sodium thiomalate).
10. The subject has Diabetes Type 1 or 2.
11. The subject has a sensitivity to hydroquinone or Retin-A.
12. The subject has evidence of a compromised immune system or hepatitis.
13. Has had microdermabrasion in past 3 months, other laser or Intense Pulsed Light treatment or chemical peels to the face in past 6 months, injectable fillers, topical retinoids, over-the-counter anti-aging products past 2 weeks.
14. Has a history of keloids or hypertrophic scarring
15. Has permanent make-up and/or is unwilling to refrain from using semi-permanent cosmetics during study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cynosure, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Patricia Krantz

Role: STUDY_DIRECTOR

Cynosure, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

NY Laser and Skin Care

New York, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CYN12-REV-TRI-AK

Identifier Type: -

Identifier Source: org_study_id